Association of Nirmatrelvir/Ritonavir Treatment with Long COVID Symptoms in an Online Cohort of Non-Hospitalized Individuals Experiencing Breakthrough SARS-CoV-2 Infection in the Omicron Era

Short Title: Nirmatrelvir/Ritonavir Treatment and Long COVID Symptoms Authors: Matthew S. Durstenfeld MD MAS^{1*}, Michael J. Peluso MD MHS MPhil DTM&H^{2*}, Feng Lin MS³, Noah D. Peyser PhD⁴, Carmen Isasi MD PhD⁵, Thomas W. Carton PhD MS⁶, Timothy J. Henrich, MD PhD⁷, Steven G. Deeks MD², Jeffrey E. Olgin MD³, Mark J. Pletcher MD MPH⁴, Alexis L. Beatty MD MAS^{3,4}, Gregory M. Marcus MD MAS³, Priscilla Y. Hsue MD¹ *Co-first authors

Affiliations

¹Division of Cardiology at ZSFG and Department of Medicine, University of California, San Francisco (UCSF), USA

²Division of HIV, Infectious Disease, & Global Medicine, UCSF, USA

³Division of Cardiology, Department of Medicine, UCSF, USA

⁴Department of Epidemiology and Biostatistics, UCSF, USA

⁵Department of Epidemiology & Population Health, Albert Einstein College of Medicine

⁶Louisiana Public Health Institute

⁷Department of Experimental Medicine, UCSF, USA

Corresponding author:

Matthew S. Durstenfeld, MD MAS Division of Cardiology, UCSF at Zuckerberg San Francisco General Hospital 1001 Potrero Avenue, 5G8 San Francisco, CA 94110, USA

Tel: +1 628 206 5562; Fax: +1 628 206 5447

e-mail: matthew.durstenfeld@ucsf.edu

twitter: @durstenfeld

Word Count: 3000

Author Contributions: Drs. Durstenfeld, Peluso, Henrich, Deeks, and Hsue designed the study with input from the CCS Executive Steering Committee including Drs. Marcus, Beatty, Olgin, Pletcher, and Peyser. Ms. Lin and Dr. Durstenfeld conducted the analyses. Dr. Peyser oversaw data management. Drs. Durstenfeld and Peluso wrote the first draft of the manuscript. Dr. Isasi and Dr. Carton recruited participants and provided critical input on the manuscript. All authors provided critical input and approved of the manuscript.

Disclosures/Conflicts of Interest: Dr. Peluso has served as a consultant for AstraZeneca and Gilead Sciences, outside the submitted work. Dr. Beatty was formerly employed by (2018-2019) and held stock in (2019-2021) Apple Inc. All other authors report no conflicts.

Acknowledgements: We would like to thank all of the research participants and all of the Patient-Centered Outcomes Research Institute sites and investigators who recruited participants.

Funding: Eureka Research Platform is supported by NIH/NIBIB 3U2CEB021881-05S1. The COVID-19 Citizen Science Study is supported by Patient-Centered Outcomes Research Institute (PCORI) contract COVID-2020C2-10761 and Bill and Melinda Gates Foundation contract INV-017206. Dr. Durstenfeld is supported by NIH/NHLBI grant K12HL143961.

Abstract

Background: Oral nirmatrelvir/ritonavir is a treatment for COVID-19, but whether treatment during the acute phase reduces the risk of developing Long COVID is unknown.

Methods: Using the Covid Citizen Science (CCS) online cohort, we surveyed individuals who reported their first SARS-CoV-2 positive test between March and August 2022 regarding Long COVID symptoms. We excluded those who were pregnant, unvaccinated, hospitalized for COVID-19, or received other antiviral therapy. The primary exposure was oral nirmatrelvir/ritonavir. The primary outcome was the presence of any Long COVID symptoms reported on cross-sectional surveys in November and December 2022. We used propensity-score models and inverse probability of treatment weighting to adjust for differences in treatment propensity. Our secondary question was whether symptom or test positivity rebound were associated with Long COVID.

Results: 4684 individuals met the eligibility criteria, of whom 988 (21.1%) were treated and 3696 (78.9%) were untreated; 353/988 (35.7%) treated and 1258/3696 (34.0%) untreated responded to the survey. Median age was 55 years and 66% were female. We did not identify an association between nirmatrelvir/ritonavir treatment and Long COVID symptoms (OR 1.15; 95%CI 0.80-1.64). Among n=666 treated with nirmatrelvir/ritonavir who responded who responded to questions about rebound, rebound symptoms or test positivity were not associated with Long COVID symptoms (OR 1.34; 95%CI 0.74-2.41; p=0.33).

Conclusions: Within this cohort, treatment with nirmatrelvir/ritonavir among vaccinated, non-hospitalized individuals was not associated with lower prevalence of Long COVID symptoms or severity of Long COVID. Experiencing rebound symptoms or test positivity is not strongly associated with developing Long COVID.

Introduction

Symptoms after SARS-CoV-2 may persist as Long COVID, a type of post-acute segualae of SARS-CoV-2 infection (PASC) defined as unexplained symptoms attributed to COVID-19 that are present at least 90 days following initial infection and persist for at least 2 months [1]. There are no treatments yet identified to reduce the risk of developing Long COVID. Vaccination reduces but does not eliminate the risk of Long COVID [2]. Higher acute viral load or prolonged viral shedding may be associated with increased risk of Long COVID [3, 4]. Recent studies suggest viral persistence in a subset of individuals with post-acute sequelae of COVID-19, including prolonged gastrointestinal shedding, ongoing Spike and Nucleocapsid antigen in neuronal and astrocytic exosomes, and evidence of persistent viral RNA or proteins in deep tissues [5-8]. Among high-risk non-hospitalized individuals with symptomatic COVID-19, nirmatrelvir, a novel oral orally administered severe acute respiratory syndrome coronavirus 2 main protease (M_{DD}) inhibitor in combination with ritonavir reduces viral load and progression to severe disease [9]. Although anecdotal reports suggest that nirmatrelvir/ritonavir treatment during acute SARS-CoV-2 infection may improve Long COVID symptoms [10-12], this has not been replicated in an observational target-trial emulation which found no difference in the incidence of EHR-diagnosed post-COVID conditions after 30 days among those treated with nirmatrelvir/ritonavir [13]. However, use of EHR-based diagnosis of post-COVID conditions, which rely on patient reporting and clinician documentation of medical diagnoses, may not capture the possible treatment effect on Long COVID symptoms.

Therefore, the objectives of this study were to test the hypothesis that nirmatrelvir/ritonavir treatment during acute SARS-CoV-2 infection is associated with a reduction in patient-reported Long COVID symptoms at least 90 days after acute infection, and secondly whether patient-reported rebound of acute symptoms or rebound test-positivity after treatment with nirmatrelvir/ritonavir is associated with Long COVID symptoms. We hypothesized

that treatment with nirmatrelvir/ritonavir would be associated with lower risk and rebound with higher risk of Long COVID symptoms.

Methods

Design, Setting, and Participants

The COVID-19 Citizen Science (CCS) Study is an online cohort study mostly of United States residents hosted on the Eureka Research Platform by the University of California, San Francisco [14]. Recruitment occurred through email invitations to existing participants in other Eureka studies, referrals from partner organizations, press releases, and word of mouth. To participate, individuals must be at least 18 years old, register for a Eureka Research Platform account with an Android, iPhone, or on the web-based study, agree to participate in English and provide electronic consent. After consenting, participants complete baseline surveys and are subsequently asked to complete regular surveys. This study included data collected from March 26, 2020 to December 22, 2022. For the primary analyses, we included individuals who reported their first positive SARS-CoV-2 test (antigen or PCR) in March 2022 through August 2022. Outcomes were ascertained only for those who responded to surveys about Long COVID symptoms sent out in November 2022 and December 2022. The primary outcome was patient-reported Long COVID symptoms at least 90 days after acute SARS-CoV-2 infection [1].

Inclusion and Exclusion Criteria

We included CCS participants with first-reported positive SARS-CoV-2 antigen or PCR test starting in March 2022. Participants were excluded if they had ever reported a positive test for SARS-CoV-2 prior to March 2022. To ascertain the possible treatment effect of nirmatrelvir/ritonavir compared to no treatment, we excluded those who received other antiviral treatment (molnupiravir, remdesivir, and monoclonal antibodies). Due to very small numbers of

individuals hospitalized for COVID-19 (n=1 in each group) and because >98% of individuals were vaccinated prior to SARS-CoV-2 infection we limited the primary analysis to non-hospitalized, vaccinated individuals. Finally, because no pregnant individuals were treated, we excluded individuals known to be pregnant from the control group.

Exposures

The primary exposure was self-reported treatment with nirmatrelvir/ritonavir within 30 days of first reported positive SARS-CoV-2 antigen or PCR test on a weekly survey from March 2022-August 2022. Participants who self-reported taking nirmatrelvir/ritonavir were subsequently invited to respond to a survey in December 2022 to assess for rebound symptoms or test positivity. Rebound symptoms were defined as symptom worsening after initial improvement ("Did your COVID-related symptoms worsen after initially improving while taking or within a few days after completing Paxlovid?"). Rebound test positivity was defined as testing negative ("Did you ever test negative while taking Paxlovid or within 2 weeks after completing Paxlovid?") and then positive on antigen test after completing treatment ("Did you subsequently test positive within two weeks of stopping Paxlovid?").

Outcomes

The primary outcome was ≥1 self-reported Long COVID symptom more than 90 days after first SARS-CoV-2 positive test on a cross-sectional survey distributed in November 2022 that asked about presence, duration, and severity of Long COVID symptoms using a non-validated instrument as we have previously published [15]. Symptoms queried included fatigue, shortness of breath, confusion, headache, altered taste and smell, joint pain, muscle aches, cough, chest pain, scratchy throat, nausea, vomiting, diarrhea, fever, chills, red or painful eyes, sore throat, and other.

Other variables

Other variables were self-reported by participants including demographics, medical history, vaccine history, and lifestyle factors as we have previously reported [15]. Only body mass index had >1% of data missing (650 missing, 40%). For the propensity adjusted model, we imputed missing body mass index from age, sex, race/ethnicity, and past medical history.

Statistical Analysis

The analysis plan was developed prior to data collection. First, we compared individuals who did and did not receive nirmatrelvir/ritonavir using Chi-squared tests for categorical variables and T-tests for continuous variables. We used logistic regression models adjusted first for age, sex, and time since COVID-19 diagnosis, and then with past medical history and substance use added. Next we modeled propensity to take nirmatrelvir/ritonavir using logistic regression models including all individuals who met the inclusion/exclusion criteria regardless of whether they responded to the cross-sectional Long COVID survey including age, sex, race, ethnicity, socioeconomic status, education, employment, past medical history, substance use, number of vaccines. After checking the Hosmer-Lemshow goodness of fit and balance of covariates by propensity score quintile, we used logistic regression models to model the association between use of nirmatrelvir/ritonavir and self-reported Long COVID among survey respondents adjusted for age, sex, time since SARS-CoV-2 test positivity, and the cubic spline of the propensity. As a sensitivity analysis, we repeated the analysis using inverse probability of treatment weighting, truncating extreme weights >95th percentile. For analyses of rebound, we used Fisher's exact test for unadjusted analyses as we did not expect age or sex to be associated with rebound so we did not consider them to be likely to be confounders. Analyses were conducted in SAS version 9.4 and STATA 17.0. Sample size was not determined a priori.

Results Reporting and Informed Consent

Results are reported in accordance with STROBE guidelines.[16] All participants provided digitally-signed informed consent. The study was reviewed and approved by the UCSF Institutional Review Board (#17-21879).

Results

Within the CCS, 4684 individuals reported their first positive test for SARS-CoV-2 during the study period and met the eligibility criteria, of whom 988 (21.1%) were treated with nirmatrelvir/ritonavir and 3696 (78.9%) were not treated (Figure 1). As expected based on prescribing guidelines [17], individuals treated with nirmatrelvir/ritonavir were older, more likely to be male, and had more comorbidities including hypertension, diabetes, asthma, sleep apnea, and cardiovascular disease (Table 1). There were no differences in the number of vaccines received prior to infection or the mean number of days since infection. Among those eligible, 353/988 (35.7%) treated and 1258/3696 (34.0%) untreated individuals responded to the Long COVID cross-sectional survey. Demographics, comorbidities, and time since SARS-CoV-2 infection were similar among respondents to the Long COVID survey compared to the overall cohort (Appendix Table 1).

Association of nirmatrelvir/ritonavir treatment with Long COVID symptoms

Among those treated with nirmatrelvir/ritonavir who responded to the Long COVID survey, 57/353 (16.1%) reported Long COVID symptoms compared to 176/1258 (14.0%) who were not treated (OR 1.18; 95%CI 0.84-1.65; p=0.31). As shown in Figure 2, in the propensity-adjusted model, treatment with nirmatrelvir/ritonavir among vaccinated, non-hospitalized individuals was not associated with self-reported Long COVID symptoms (OR 1.15; 95%CI 0.80-1.64; p=0.45). Results were similar when adding race/ethnicity, past medical history, and substance use to the model (OR 1.17; 95%CI 0.81-1.69). Similarly, using inverse probability of

treatment weighting as an alternative analytic strategy yielded the same estimate (OR 1.17; 95%CI 0.80-1.71; p=0.43).

Among those treated with nirmatrelvir/ritonavir reporting at least one Long COVID symptom, the median number of Long COVID symptoms was 1 (IQR 1-4) compared to 2 (IQR 1-4) among those untreated (p=0.35); the mean number of symptoms was 2.86±2.42 and 3.06±2.54, respectively (p=0.70). Few individuals reported at least one severe or very severe Long COVID symptom in either group: 6 (1.7% overall, 10.5% with Long COVID) among the treated and 18 (1.4% overall, 10.2% with Long COVID) among the untreated (p=0.18); because few participants reported many or severe symptoms, we could not exclude an effect on symptom severity.

Rebound

Among 666 individuals who responded to the rebound survey at least 30 days after taking nirmatrelvir/ritonavir for acute SARS-CoV-2 infection, 139/650 (21%) reported rebound symptoms. Among those who repeated antigen testing after completing treatment, 97/377 (25.7%) reported rebound test positivity. In total, 174/666 (26.1%) experienced rebound symptoms or test positivity. Among those with rebound, 18/166 (10.8%) reported 1 or more Long COVID symptom compared to 39/468 (8.3%) who did not experience rebound (OR 1.34; 95%Cl 0.74-2.41; p=0.33). Results were similar when considering rebound symptoms (9.9% vs 8.4%; OR 1.20; 95%Cl 0.62-2.31; p=0.59) or rebound test positivity (10.8% vs 7.7%; OR 1.45; 95%Cl 0.66-3.21; p=0.36). Results were similar using a more sensitive outcome of those who had not experienced full recovery (14.9% with rebound vs 12.8% without rebound; OR 1.20; 95%Cl 0.73-1.96; p=0.48).

Results were similar when limiting analysis to respondents who completed treatment more than 90 days prior (n=157). Of those, 31/157 (20.2%) experienced rebound symptoms and 17/84 (19.7%) had a rebound test positivity with 38/157 (24.2%) classified as having any

rebound. Only 2/38 (5.2%) individuals who experienced rebound symptoms reported Long COVID symptoms compared to 19/119 (16.0%) who did not experience rebound (p=0.11). No individuals who experienced rebound test positivity reported Long COVID symptoms (0/17) compared to 10/67 (14.9%) among those with repeated testing without rebound test positivity (p=0.20).

Discussion

Within an online observational cohort, we did not find evidence that treatment with oral nirmatrelvir/ritonavir during the acute phase of COVID-19 was associated with a lower prevalence of patient-reported Long COVID symptoms at least 90 days after infection among vaccinated, non-hospitalized individuals experiencing their first known SARS-CoV-2 infection. We did not find a significant effect of treatment on the number of Long COVID symptoms or severe symptoms, although these endpoints were limited by a small number of people experiencing more than 1 symptom or severe symptoms. Similarly, we did not find that rebound symptoms or test positivity after treatment with nirmatrelvir/ritonavir were associated with a statistically significant effect on Long COVID symptoms.

Prior studies of nimatrelvir/ritonavir focus on acute symptoms

Prior studies of oral nimatrelvir/ritonavir, including two randomized clinical trials, EPIC-HR and EPIC-SR, have focused on acute outcomes of SARS-CoV-2 infection. EPIC-HR demonstrated a reduction in hospitalization and mortality by day 28 among those at high risk of disease progression treated with nirmatrelvir/ritonavir compared to placebo [9], but the EPIC-SR study of standard risk individuals was stopped early after there was no benefit in improvement of symptoms or progression to severe disease [18]. A number of "real-world" observational studies have mostly found similar results, with reductions in hospitalization and mortality among higher risk individuals as well as vaccinated individuals [19-23]. Others have demonstrated

faster viral clearance with nirmatrelvir/ritonavir [24, 25]; as higher viral loads and prolonged viral shedding have been previously associated with risk of Long COVID [3, 4], there is a strong rationale for the hypothesis that treatment with nirmatrelvir/ritonavir may lower the risk of Long COVID. Secondly, in this cohort, we have previously shown that the number of symptoms during acute infection is associated with Long COVID symptoms independent of vaccination and variant wave [15], but whether reducing acute symptoms with antiviral therapy reduces risk of Long COVID has not been demonstrated.

Our study in context of studies of nirmatrelvir/ritonavir on post-COVID outcomes

Only two [yet unpublished] studies have considered the potential impact of oral nirmatrelvir/ritonavir at the time of acute infection on longer term post-COVID outcomes, with contradictory results despite both including Veterans and examining EHR-diagnosed post-COVID conditions by ICD-10 diagnostic codes as the outcome of interest [13, 26]. Bajema et al found a benefit on acute outcomes within 30 days but did not find a reduction in EHR-diagnosed post-COVID conditions among the treated at 6 months, whereas Xie et al found a decrease in post-COVID conditions, hospitalizations, and mortality among treated individuals from 30-90 days. One possible explanation for the difference is that Bajema et al used a target-trial emulation study design, which is more robust to common pitfalls of observational studies of treatment effects. Both studies focused on an older, sicker patient population and are limited by differential outcome ascertainment, differential misclassification, and lack of ascertainment that these ICD-codes correspond to patient symptoms.

In contrast to EHR-based studies focused on ascertainment of post-COVID-conditions using ICD-10 codes, our study evaluated whether treatment with oral nimatrelvir/ritonavir has an impact on patient-reported Long COVID symptoms, as well as the association between patient-reported rebound and subsequent Long COVID symptoms. Our outcome of patient-reported symptoms is a closer approximation of the condition of interest (Long COVID, defined as

unexplained symptoms persisting for >90 days following initial infection in accordance with the WHO definition) [1]. Our finding that nimatrelvir/ritonavir treatment during acute infection is not associated with lower odds of Long COVID is consistent with the Bajema et al report from the VA that there was no difference in post-COVID conditions at 6 months [13]. Data on the effect of other acute therapies including remdesivir on Long COVID symptoms have been mixed, with Italian observational data suggesting a benefit with remdesivir [27], but the Finish randomized SOLIDARITY trial did not demonstrate a difference in Long COVID with remdesivir compared to placebo [28]. One study suggested a benefit from metformin but not ivermectin or fluvoxamine [29], but a randomized platform study did not find that doxazosin, fluvoxamine, fluvoxamine in combination with inhaled budesonide, interferon-lambda, ivermectin, or metformin had any impact on Long COVID symptoms or quality of life [30].

Rebound and Long COVID

We found a higher proportion with clinical rebound than reported in the literature [31], but did not identify an effect of post-treatment rebound on the later development of Long COVID symptoms. Since antivirals entered widespread use, there has been intense interest in this phenomenon, and some case reports have clearly demonstrated the development of Long COVID among those with post-treatment rebound [10]. The observation that anti-viral associated rebound is not associated with Long COVID in this study suggests that the potential for treatment-related rebound symptoms should not discourage antiviral use in the first place, and that individuals experiencing this phenomenon are not uniquely at risk for Long COVID. However, rebound test positivity was common in the early days of the pandemic [32]; because of the way our data were collected, we were not able to determine whether the presence of rebound unrelated to treatment increases the likelihood of an individual experiencing Long COVID. If this were the case, it is possible that rebound symptoms could be used as a prognostic marker of later post-acute symptoms.

Role of treatment for Long COVID

Although a 5 day course of oral nimatrelvir/ritonavir at the time of acute test positivity in this low-risk, vaccinated population was not associated with a reduction in Long COVID, our study does not consider whether nimatrelvir/ritonavir may be effective at treating Long COVID, which is currently under investigation in one ongoing and two planned clinical trials (NCT05576662, NCT05595369, NCT05668091).

Limitations

The primary limitations of our study arise from its observational nature. The cohort was relatively homogeneous; most individuals identified as white with advanced education, limiting the generalizability of the findings, in large part because we limited this study to first infections and thus only those privileged enough to avoid infection until March 2022 were included. We relied on participant self-report of nirmatrelvir/ritonavir treatment and Long COVID symptoms. SARS-CoV-2 testing and nirmatrelvir/ritonavir use were collected longitudinally at the time of positive test and treatment, respectively, limiting the role of recall bias in ascertaining exposure. We did not include the number of symptoms during acute infection in our models as we could not determine their temporal relation to treatment. Participant self-report of Long COVID symptoms is currently the gold-standard for ascertainment of the outcome. The survey response rate was non-differential between treated and untreated individuals. We note that our study differs from EHR-based reports in that we assessed Long COVID symptoms rather than the presence of PASC as measured through clinician-coded ICD-10 codes. We therefore could not determine whether treatment during the acute phase had an impact on other important postacute outcomes like cardiovascular sequelae, diabetes, or other medical diagnoses. We also could not ascertain whether treatment had an effect on objectively measured post-COVID

outcomes (e.g., exercise capacity [33], neurocognitive performance [34], or other objectively measurable physiologic perturbations) potentially associated with Long COVID which may lend additional specificity to the outcome. We used propensity scores and inverse probability of treatment weighting to adjust for baseline differences between propensity of treatment between the treated and untreated, but residual confounding may still bias the results. An additional limitation regarding the rebound test positivity analysis is that tests were not performed systematically, and results were based on participant test self-report. We did not assess for rebound symptoms among those not treated.

Conclusions

Among vaccinated, non-hospitalized adult participants in the COVID Citizen Science online cohort, we did not find that treatment with oral nirmatrelvir/ritonavir during the acute phase of SARS-CoV-2 infection was associated with lower odds of Long COVID symptoms more than 90 days after index infection. Among those treated, we did not find that rebound was associated with a large increase in Long COVID symptoms.

References

- 1. Soriano JM, J; Diaz, JV; Murthy, S;; Relan, P. A clinical case definition of post COVID-19 condition by a Delphi consensus. In: Organization WH. 2021.1 ed:, **2021**.
- 2. Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine **2023**.
- 3. Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell **2022**; 185(5): 881-95 e20.
- 4. Antar AAR, Yu T, Demko ZO, et al. Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. medRxiv **2023**: 2023.01.18.23284742.
- 5. Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature **2022**; 612(7941): 758-63.
- 6. Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis **2022**.
- 7. Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y) **2022**; 3(6): 371-87 e9.
- 8. Peluso MJ, Deeks SG, Mustapic M, et al. SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. Ann Neurol **2022**; 91(6): 772-81.
- 9. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med **2022**; 386(15): 1397-408.
- 10. Peluso MJ, Anglin K, Durstenfeld MS, et al. Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies. Pathog Immun **2022**; 7(1): 95-103.
- 11. Visvabharathy L, Orban ZS, Koralnik IJ. Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence. Front Med (Lausanne) **2022**; 9: 1003103.
- 12. Geng LN, Bonilla HF, Shafer RW, Miglis MG, Yang PC. The Use of Nirmatrelvir-ritonavir in a Case of Breakthrough Long COVID. Exploratory Research and Hypothesis in Medicine **2023**; 000(000): 000-.
- 13. Bajema KL, Berry K, Streja E, et al. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes. medRxiv **2022**: 2022.12.05.22283134.
- 14. Beatty AL, Peyser ND, Butcher XE, et al. The COVID-19 Citizen Science Study: Protocol for a Longitudinal Digital Health Cohort Study. JMIR Res Protoc **2021**; 10(8): e28169.
- Durstenfeld MS, Peluso MJ, Peyser ND, et al. Factors Associated with Long Covid Symptoms in an Online Cohort Study. Open Forum Infectious Diseases **2023**.
- 16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med **2007**; 147(8): 573-7.
- 17. Administration FaD. Fact Sheet for Healthcare Providers. 2022.
- 18. Pfizer. Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA. **2022**.
- 19. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients. Clin Infect Dis **2022**; 76(3): e342-e9.

- 20. Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System: A Population-Based Cohort Study. Ann Intern Med **2023**; 176(1): 77-84.
- 21. Wai AK, Chan CY, Cheung AW, et al. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg Health West Pac **2023**; 30: 100602.
- 22. Shah MM, Joyce B, Plumb ID, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19 United States, April-September 2022. Am J Transplant **2023**; 23(1): 150-5.
- 23. Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis **2022**; 22(12): 1681-93.
- 24. Qi T, Jin Y, Wang H, et al. Nirmatrelvir-ritonavir Therapy and COVID-19 Vaccination Improve Clinical Outcomes of SARS-CoV-2 Omicron Variant Infection. J Med Virol **2023**.
- 25. Wang Y, Zhao D, Liu X, Chen X, Xiao W, Feng L. Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants. J Med Virol **2023**; 95(1): e28443.
- 26. Xie Y CT, Al-Aly Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19 medRxiv **2022**.
- 27. Boglione L, Meli G, Poletti F, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? Qjm **2022**; 114(12): 865-71.
- 28. Nevalainen OPO, Horstia S, Laakkonen S, et al. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nature Communications **2022**; 13(1): 6152.
- 29. Bramante CT, Buse JB, Liebovitz D, et al. Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up. medRxiv **2022**.
- 30. Reis G, Wilson L, Ayers D, et al. Effectiveness of early-treatment interventions on self-reported long COVID: A multi-arm, multi-stage adaptive platform control trial. Preprint at researchsquareorg **2022**.
- 31. Ranganath N, O'Horo JC, Challener DW, et al. Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. Clinical Infectious Diseases **2022**; 76(3): e537-e9.
- 32. Uhm JS, Ahn JY, Hyun J, et al. Patterns of viral clearance in the natural course of asymptomatic COVID-19: Comparison with symptomatic non-severe COVID-19. Int J Infect Dis **2020**; 99: 279-85.
- 33. Durstenfeld MS, Peluso MJ, Kaveti P, et al. Inflammation during early post-acute COVID-19 is associated with reduced exercise capacity and Long COVID symptoms after 1 year. Preprint at medrxivorg (Posted May 19, 2022) **2022**.
- 34. Apple AC, Oddi A, Peluso MJ, et al. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol **2022**; 9(2): 221-6.

Tables

Table 1. Baseline Demographics and Medical History

	Treated with nirmatrelvir/ritonavir, N = 988		SARS-CoV-2 infected, untreated, N = 3696		
Characteristic	N	Mean ± std or n(%)	N	Mean ± std or n(%)	P value treated vs not
Age, Mean +/- SD	984	59.84 ± 13.30	3678	52.10 ± 14.02	0.0000
Female sex assigned at birth	981	604 (61.6%)	3681	2472 (67.2%)	0.0010
Gender identity					0.0008
Male	981	376 (38.3%)	3680	1196 (32.5%)	
Female	981	592 (60.3%)	3680	2449 (66.5%)	
Transgender Woman (MTF)			3680	6 (0.2%)	
Transgender Man (FTM)	981	3 (0.3%)	3680	3 (0.1%)	
Genderqueer	981	10 (1.0%)	3680	16 (0.4%)	

Other	981	3 (0.3%)	3680	13 (0.4%)	
Race/Ethnicity					
White	976	907 (92.9%)	3652	3315 (90.8%)	0.0342
Black or African	976	18 (1.8%)	3652	101 (2.8%)	0.1062
Americian					
Asian	976	51 (5.2%)	3652	241 (6.6%)	0.1169
Native Hawaiian or	976	3 (0.3%)	3652	12 (0.3%)	0.9175
Pacific Islander					
American Indian or	976	11 (1.1%)	3652	54 (1.5%)	0.4070
Alaska Native					
Other/Don't know	976	31 (3.2%)	3652	101 (2.8%)	0.4936
Hispanic Ethnicity	981	40 (4.1%)	3681	252 (6.8%)	0.0015
MacArthur SES, Mean +/- SD	981	7.21 ± 1.56	3679	7.11 ± 1.52	0.0636
Highest Educational Level					0.2052
No high school degree	981	2 (0.2%)	3681	5 (0.1%)	

High school graduate (or	981	23 (2.3%)	3681	83 (2.3%)	
equivalent)					
College degree (including	981	438 (44.6%)	3681	1795 (48.8%)	
associate's)					
Graduate degree	981	510 (52.0%)	3681	1762 (47.9%)	
Other	981	8 (0.8%)	3681	36 (1.0%)	
US resident	988	987 (99.9%)	3696	3582 (96.9%)	0.0000
BMI, Mean +/- SD	640	28.86 ± 7.25	2145	27.69 ± 6.41	0.0001
Tobacco use	988	36 (3.6%)	3692	219 (5.9%)	0.0049
Marijuana use	988	68 (6.9%)	3692	294 (8.0%)	0.2588
Alcoholic drinks/week pre-	988	4.12 ± 5.32	3644	4.38 ± 5.49	0.1886
COVID, Mean +/- SD					
Financial insecurity pre-COVID	954	171 (17.9%)	3506	619 (17.7%)	0.8469
Average Anxiety (GAD-7) pre-	957	3.60 ± 3.85	3515	3.83 ± 3.80	0.0926
COVID, mean +/- SD					
Average Depression (PHQ-8)	955	3.81 ± 3.91	3513	3.96 ± 3.95	0.2997
pre-COVID, mean +/- SD					

Hypertension	988	368 (37.2%)	3693	909 (24.6%)	0.0000
Diabetes	988	88 (8.9%)	3693	178 (4.8%)	0.0000
Coronary Artery Disease	988	59 (6.0%)	3693	131 (3.5%)	0.0006
Heart Failure	988	6 (0.6%)	3693	33 (0.9%)	0.4546
Stroke or Transient Ischemic Attack	988	30 (3.0%)	3693	75 (2.0%)	0.1376
Atrial Fibrillation	988	61 (6.2%)	3693	135 (3.7%)	0.0019
Sleep Apnea	987	204 (20.7%)	3693	418 (11.3%)	0.0000
Chronic Obstructive Pulmonary Disease	988	26 (2.6%)	3693	53 (1.4%)	0.0338
Asthma	988	117 (11.8%)	3693	296 (8.0%)	0.0005
Cancer	988	95 (9.6%)	3693	188 (5.1%)	0.0000
Immunodeficiency	988	47 (4.8%)	3693	64 (1.7%)	0.0000
HIV	988	11 (1.1%)	3693	13 (0.4%)	0.0062
Anemia	988	97 (9.8%)	3693	392 (10.6%)	0.5647

Days since COVID-19, mean +/-SD	353	161.74 ± 39.62	1258	165.44 ± 45.19	0.1627
Number of acute COVID-19 symptoms, mean +/- SD	988	5.14 ± 2.30	3619	4.82 ± 2.33	0.0002
Number of Long COVID Symptoms, median (IQR)		1 (IQR 1-4)		2 (IQR 1-4)	0.35
Number of SARS-CoV-2 vaccines received prior to COVID-19	988	2.48 ± 0.62	3696	2.45 ± 0.63	0.3024
Number of Vaccines received after COVID-19	988	0.01 ± 0.10	3696	0.01 ± 0.12	0.3748

Table 2: Unadjusted Outcomes among Survey Respondents (n=1611)

	Nirmatrelvir/ ritonavir treated	Not treated	Total
≥1 Long COVID symptom	57 (24.5%)	296 (21.5%)	353 (21.9%)
No Long COVID symptoms	176 (78.5%)	1082 (75.5 %)	1258 (78.1%)
Total	233	1378	1611

Figures

Figure 1. Participant Flow Diagram




Figure 1 Legend: Flow diagram for participants included in the primary analysis.

Figure 2. Forest Plot of Treatment Effect of Oral Nirmatrelvir/ritonavir on Long COVID symptoms




Figure 2 Legend: In all models, treatment with oral nirmatrelvir/ritonavir was associated with higher odds of patient reported Long COVID symptoms with confidence intervals that cross 1, which suggests that treatment is not beneficial in reducing the risk of Long COVID. Model 3, the pre-specified primary result, includes age, sex, and time since SARS-CoV-2 infection, and the restricted cubic spline of the propensity score. Model 1 includes age, sex, and time since SARS-CoV-2 infection. Model 2 includes age, sex, time since SARS-CoV-2 infection, race/ethnicity, past medical history and substance use. Model 4 is the propensity-adjusted version of Model 2. Finally, Model 5 incorporates inverse probability of treatment weighting and age, sex, and time since SARS-CoV-2 infection.